VolitionRx reported third-quarter 2026 revenue of $1.6 million, a 157% increase from $0.6 million a year earlier, driven by the accelerated recognition of deferred revenue. The company's operating loss narrowed 35% year over year to $3.3 million, as higher revenue and lower operating costs offset the gap, while operating expenses fell 14% to $4.9 million under a company-wide cost-reduction program. Net loss for the quarter was $3.8 million, including $0.4 million in non-cash charges tied to convertible notes. Year-to-date revenue through September 30 reached $3.0 million, up 134% from $1.3 million in the first nine months of 2025.
The cost reductions have reached the workforce, with headcount down 28% compared with the same point in 2025. Management said it aims to bring monthly operating cash burn below $1.0 million by 2027, relying on non-dilutive sources such as licensing income and grants. The CEO and board have taken a 50% cut in base salary until a substantial licensing deal is executed. Cash stood at $2.4 million as of September 30, 2026, up from $1.1 million at the end of 2025, after $5.2 million in net proceeds from an at-the-market facility during the quarter.S1
The balance sheet improved sharply. Since June 30, 2026, the company has paid down $5.0 million in convertible note debt, including fully extinguishing a $7.5 million note, and in October made a $1.7 million partial prepayment on a $2.4 million note. About $0.7 million in convertible notes remains outstanding.S1
On the product side, the company highlighted its Capture-Seq technology. It cited a clinical manuscript, submitted for peer review, reporting 97% specificity and an 86% detection rate for feline lymphomas, and said a $5.0 million contractual milestone payment is expected to unlock on peer-reviewed publication of that study. Management pointed to a $23.0 billion annualized total addressable market for human multi-cancer early detection and $13.0 billion for minimal residual disease applications in human liquid biopsy, which it is pursuing through active licensing discussions.S1
The company also referenced sepsis, citing 166.0 million cases worldwide annually and all-cause sepsis-related deaths representing 31.5% of global deaths in 2021. A trauma study reported average H3.1 levels of 359.7 nanograms per milliliter in trauma patients versus 22.3 in healthy subjects. A French government program, DETECSEPS, provided EUR 6.5 million in cash for sepsis early detection.S1
